Soluble guanylate cyclase activators

US9611278B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Xiaoqing Han · Edison, US
• Alan Whitehead · Scotch Plains, US
• Subharekha Raghavan · Teaneck, US
• Jonathan Groeper · Metuchen, US
• Jian Guo · Lawrence, US
• Yong Zhang · Plainsboro, US

Key dates

• Filing date: Dec 5, 2014
• Grant date: Apr 4, 2017
• Expiry date: Dec 5, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P13/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.